Previous 10 | Next 10 |
2023-11-13 08:22:15 ET Losers: Aclaris Therapeutics ( ACRS ) -85% announces top-line results from 12-Week phase 2b trial of Oral Zunsemetinib . Verve Therapeutics ( VERV ) -38% . Syntec Optics Holdings ( OPTX ) -10% . Motus GI Holdings ( MOTS ...
2023-11-13 06:59:53 ET More on Verve Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve shares surge to three-month high following Q3 update Verve Therapeutics GAAP EPS o...
LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans...
2023-11-10 16:50:48 ET Summary Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program for Sickle Cell Disease is way behind CRISPR Therap...
2023-11-09 05:57:00 ET The tail end of this fall's earnings season has been more than a little exciting for a pair of healthcare-related growth stocks. Shares of TransMedics Group (NASDAQ: TMDX) and Verve Therapeutics (NASDAQ: VERV) rose more than 50% in the first week of No...
2023-11-07 13:13:08 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Ver...
2023-11-07 08:21:01 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Gen...
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s Acquisition of Product Rights to Verve...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Verve Therapeutics Inc. (VERV) is expected to report $-0.91 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...